Oxford GlycoSciences plc said its lead product, Zavesca, a treatment for Gaucher's disease received marketing authorization from the European Commission and the company plans to launch the product on the European market in the spring. (Bioworld International)

Oxford GlycoSciences plc said its lead product, Zavesca, a treatment for Gaucher's disease received marketing authorization from the European Commission and the company plans to launch the product on the European market in the spring. (Bioworld International)